Anti-proliferative activity of CC-5013 in 5q-myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines.

被引：0
|
作者：
Gandhi, AK [1 ]
Naziruddin, S [1 ]
Verhelle, D [1 ]
Brady, H [1 ]
Schafer, P [1 ]
Stirling, D [1 ]
机构：
[1] Celgene Corp, Warren, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6618
引用
收藏
页码：587S / 587S
页数：1
相关论文
共 8 条
  • [1] Scutellaria baicalensis, a herbal medicine: Anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines
    Kumagai, Takashi
    Muller, Claudia I.
    Desmond, Julian C.
    Imai, Yasufumi
    Heber, David
    Koeffler, H. Phillip
    LEUKEMIA RESEARCH, 2007, 31 (04) : 523 - 530
  • [2] Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease.
    Buesche, G
    Dieck, S
    Giagounidis, A
    Bock, O
    Wilkens, L
    Schlegelberger, B
    Knight, R
    Bennett, J
    Aul, C
    Kreipe, HH
    BLOOD, 2005, 106 (11) : 113A - 113A
  • [3] Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study.
    List, AF
    Dewald, G
    Bennett, J
    Giagounadis, A
    Raza, A
    Feldman, E
    Powell, B
    Greenberg, P
    Zeldis, J
    Knight, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 2S - 2S
  • [4] B-acute lymphoblastic leukemia/lymphoma (B-ALL) with precedent or concurrent myelodysplastic syndrome (MDS) with deletion 5q
    Joo, Jin Woo
    Konoplev, Sergej
    McDonnell, Timothy J.
    Ok, Chi Young
    JOURNAL OF HEMATOPATHOLOGY, 2017, 10 (02) : 75 - 80
  • [5] B-acute lymphoblastic leukemia/lymphoma (B-ALL) with precedent or concurrent myelodysplastic syndrome (MDS) with deletion 5q
    Jin Woo Joo
    Sergej Konoplev
    Timothy J. McDonnell
    Chi Young Ok
    Journal of Hematopathology, 2017, 10 : 75 - 80
  • [6] Novel synthetic histone deacetylase inhibitor, SK-7041, has potent anti-proliferative activity in acute myeloid leukemia cell lines
    Yoon, Sung-Soo
    Bae, Eunkyung
    Park, Juwon
    Cha, Yongjun
    Lee, Young Y.
    Kim, Byoung K.
    BLOOD, 2007, 110 (11) : 839A - 839A
  • [7] Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide A case report
    Burgos, Sebastian
    Montalban-Bravo, Guillermo
    Fuente, Lucia
    Jabbour, Elias J.
    Kanagal-Shamanna, Rashmi
    Soltysiak, Kelly A.
    Garcia-Manero, Guillermo
    Mela-Osorio, Maria J.
    MEDICINE, 2019, 98 (01) : E14011
  • [8] Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations
    Jain, Preetesh
    Tang, Guilin
    Konoplev, Sergej N.
    Kanagal-Shamanna, Rashmi
    Wang, Sa A.
    Pemmaraju, Naveen
    Daver, Naval
    Estrov, Zeev
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) : 354 - 355
1